- Home
- SOC vs ARQT Comparison
SOC vs ARQT Comparison
Compare SOC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOC
- ARQT
- Stock Information
- Founded
- SOC 2020
- ARQT 2016
- Country
- SOC United States
- ARQT United States
- Employees
- SOC N/A
- ARQT N/A
- Industry
- SOC
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- SOC
- ARQT Health Care
- Exchange
- SOC Nasdaq
- ARQT Nasdaq
- Market Cap
- SOC 2.2B
- ARQT 1.6B
- IPO Year
- SOC N/A
- ARQT 2020
- Fundamental
- Price
- SOC $20.95
- ARQT $13.52
- Analyst Decision
- SOC Buy
- ARQT Strong Buy
- Analyst Count
- SOC 4
- ARQT 6
- Target Price
- SOC $26.25
- ARQT $18.80
- AVG Volume (30 Days)
- SOC 1.5M
- ARQT 2.1M
- Earning Date
- SOC 05-19-2025
- ARQT 05-06-2025
- Dividend Yield
- SOC N/A
- ARQT N/A
- EPS Growth
- SOC N/A
- ARQT N/A
- EPS
- SOC N/A
- ARQT N/A
- Revenue
- SOC N/A
- ARQT $212,819,000.00
- Revenue This Year
- SOC N/A
- ARQT $57.99
- Revenue Next Year
- SOC N/A
- ARQT $41.24
- P/E Ratio
- SOC N/A
- ARQT N/A
- Revenue Growth
- SOC N/A
- ARQT 100.03
- 52 Week Low
- SOC $10.40
- ARQT $6.99
- 52 Week High
- SOC $32.33
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- SOC 51.64
- ARQT 42.59
- Support Level
- SOC $18.26
- ARQT $12.42
- Resistance Level
- SOC $21.20
- ARQT $15.67
- Average True Range (ATR)
- SOC 1.14
- ARQT 0.87
- MACD
- SOC 0.36
- ARQT -0.03
- Stochastic Oscillator
- SOC 85.60
- ARQT 33.69
About SOC Sable Offshore Corp. Common Stock
Sable Offshore Corp is a Houston-based independent upstream company focused on responsibly developing the prolific Santa Ynez Unit in federal waters offshore California.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.